Alnylam Pharmaceuticals
$110.369876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$110.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$4.54 (+4.29%) As of 3:41 PM EDT today
+$4.54 (+4.29%) Today
Why Robinhood?
You can buy or sell ALNY and other stocks, options, ETFs, and crypto commission-free!
About ALNY
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. Read More The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Employees
1,323
Headquarters
Cambridge, Massachusetts
Founded
2002
Market Cap
12.55B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
919.84K
High Today
$111.98
Low Today
$107.67
Open Price
$108.24
Volume
504.96K
52 Week High
$134.51
52 Week Low
$65.81
Collections
ALNY News
ReutersApr 2
BRIEF-Vir And Alnylam Expand Collaboration To Advance Investigational RNAi Therapeutics Targeting Host Factors For The Treatment Of Covid-19
April 2 (Reuters) - Alnylam Pharmaceuticals Inc:
* VIR AND ALNYLAM EXPAND COLLABORATION TO ADVANCE INVESTIGATIONAL RNAI THERAPEUTICS TARGETING HOST FACTORS FOR
Analyst Ratings
77%
of 22 ratings
Buy
77%
Hold
18%
Sell
5%
ALNY Earnings
-$2.28
-$1.52
-$0.76
$0.00
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 29, Pre-Market